PI3Kδ/γ inhibition promotes human CART cell epigenetic and metabolic reprogramming to enhance antitumor cytotoxicity.
Saved in:
| Title: | PI3Kδ/γ inhibition promotes human CART cell epigenetic and metabolic reprogramming to enhance antitumor cytotoxicity. |
|---|---|
| Authors: | Funk CR; Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA., Wang S; Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA., Chen KZ; Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA., Waller A; Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA., Sharma A; Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA., Edgar CL; Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA., Gupta VA; Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA., Chandrakasan S; Division of Bone Marrow Transplant and., Zoine JT; Cell and Gene Therapy Program, Aflac Cancer and Blood Disorders Center, Department of Pediatrics, Children's Healthcare of Atlanta and Emory University School of Medicine, Atlanta, GA., Fedanov A; Cell and Gene Therapy Program, Aflac Cancer and Blood Disorders Center, Department of Pediatrics, Children's Healthcare of Atlanta and Emory University School of Medicine, Atlanta, GA., Raikar SS; Cell and Gene Therapy Program, Aflac Cancer and Blood Disorders Center, Department of Pediatrics, Children's Healthcare of Atlanta and Emory University School of Medicine, Atlanta, GA., Koff JL; Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA., Flowers CR; Cell and Gene Therapy Program, Aflac Cancer and Blood Disorders Center, Department of Pediatrics, Children's Healthcare of Atlanta and Emory University School of Medicine, Atlanta, GA.; Department of Lymphoma/Myeloma, Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston, TX; and., Coma S; Verastem Oncology Inc, Needham, MA., Pachter JA; Verastem Oncology Inc, Needham, MA., Ravindranathan S; Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA., Spencer HT; Cell and Gene Therapy Program, Aflac Cancer and Blood Disorders Center, Department of Pediatrics, Children's Healthcare of Atlanta and Emory University School of Medicine, Atlanta, GA., Shanmugam M; Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA., Waller EK; Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA. |
| Source: | Blood [Blood] 2022 Jan 27; Vol. 139 (4), pp. 523-537. |
| Publication Type: | Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: Elsevier Country of Publication: United States NLM ID: 7603509 Publication Model: Print Cited Medium: Internet ISSN: 1528-0020 (Electronic) Linking ISSN: 00064971 NLM ISO Abbreviation: Blood Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
